Table 1 Baseline characteristics of patients with HCC in the low- and high-risk groups
Characteristic | Low-risk group (n = 182) | High-risk group (n = 183) | P value |
|---|---|---|---|
Age | 0.082 | ||
< 60 | 74 (40.7%) | 91 (49.7%) | |
≥ 60 | 108 (59.3%) | 92 (50.3%) | |
Gender | 0.602 | ||
Male | 125 (68.7%) | 121 (66.1%) | |
Female | 57 (31.3%) | 62 (33.9%) | |
Race | 0.260 | ||
White | 96 (55.5%) | 86 (47.3%) | |
Asian | 69 (39.9%) | 86 (47.3%) | |
Black or african american | 7 (4.0%) | 10 (5.5%) | |
American indian or alaska native | 1 (0.6%) | 0 (0%) | |
Family cancer history | 0.158 | ||
No | 96 (60.8%) | 108 (68.4%) | |
Yes | 62 (39.2%) | 50 (31.6%) | |
m6A-RPS score, median (IQR) | 4.13 (3.96, 4.28) | 4.70 (4.56, 4.97) | < 0.001 |
OS (days), median (IQR) | 659 (395, 1354) | 469 (262, 899) | < 0.001 |
PFI (days), median (IQR) | 475 (226, 828) | 293 (106, 574) | < 0.001 |
Histologic grade | < 0.001 | ||
G1 | 32 (17.8%) | 23 (12.8%) | |
G2 | 105 (58.3%) | 70 (38.9%) | |
G3 | 39 (21.7%) | 79 (43.9%) | |
G4 | 4 (2.2%) | 8 (4.4%) | |
Child-Pugh grade | 0.303 | ||
A | 122 (92.4%) | 94 (88.7%) | |
B | 9 (6.8%) | 12 (11.3%) | |
C | 1 (0.8%) | 0 (0%) | |
Fibrosis ishak score | 0.257 | ||
0 - No fibrosis | 44 (37.9%) | 30 (32.3%) | |
1,2 - Portal fibrosis | 15 (12.9%) | 16 (17.2%) | |
3,4 - Fibrous speta | 12 (10.3%) | 15 (16.1%) | |
5 - Nodular formation and incomplete cirrhosis | 3 (2.6%) | 6 (6.5%) | |
6 - Established cirrhosis | 42 (36.2%) | 26 (28.0%) | |
Residual tumor | 0.050 | ||
R0 | 165 (92.7%) | 155 (86.1%) | |
R1 | 7 (3.9%) | 10 (5.6%) | |
R2 | 1 (0.6%) | 0 (0%) | |
RX | 5 (2.8%) | 15 (8.3%) | |
Vascular invasion | 0.040 | ||
No | 116 (71.2%) | 89 (60.1%) | |
Yes | 47 (28.8%) | 59 (39.9%) | |
T stage | < 0.001 | ||
T1 | 109 (60.6%) | 71 (38.8%) | |
T2 | 33 (18.3%) | 58 (31.7%) | |
T3 | 33 (18.3%) | 45 (24.6%) | |
T4 | 5 (2.8%) | 8 (4.4%) | |
TX | 0 (0%) | 1 (0.5%) | |
N stage | 0.076 | ||
N0 | 116 (63.7%) | 132 (72.5%) | |
N1 | 1 (0.5%) | 3 (1.6%) | |
NX | 65 (35.7%) | 47 (25.8%) | |
M stage | 0.008 | ||
M0 | 120 (65.9%) | 143 (78.1%) | |
M1 | 3 (1.6%) | 0 (0%) | |
MX | 59 (32.4%) | 40 (21.9%) | |
Pathologic stage | < 0.001 | ||
Stage I | 104 (60.8%) | 66 (38.8%) | |
Stage II | 31 (18.1%) | 53 (31.2%) | |
Stage III | 32 (18.7%) | 51 (30%) | |
Stage IV | 4 (2.3%) | 0 (0%) | |
AFP (ng/ml), median (IQR) | 10.0 (4.0, 58.0) | 26.5 (5.0, 1373.0) | 0.004 |
Albumin (g/dl), median (IQR) | 3.95 (3.50, 4.30) | 4.10 (3.50, 4.38) | 0.276 |
Creatinine (mg/dl), median (IQR) | 0.90 (0.70, 1.10) | 0.90 (0.70, 1.10) | 0.577 |
Prothrombin time (s), median (IQR) | 1.10 (1.00, 9.50) | 1.10 (1.00, 8.85) | 0.136 |
Platelet count, median (IQR) | 208.0 (157.5, 292.0) | 213.5 (166.0, 303.75) | 0.497 |
